These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18440103)

  • 21. Protection against influenza infection by cytokine-enhanced aerosol genetic immunization.
    Orson FM; Kinsey BM; Densmore CL; Nguyen T; Wu Y; Mbawuike IN; Wyde PR
    J Gene Med; 2006 Apr; 8(4):488-97. PubMed ID: 16389596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation and characterization of an H5N1 avian influenza virus hemagglutinin glycoprotein pseudotyped lentivirus.
    Zhang S; Xiao L; Zhou H; Yu Z; Chen H; Guo A; Jin M
    J Virol Methods; 2008 Dec; 154(1-2):99-103. PubMed ID: 18812190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
    Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trypsin pre-treatment corrects SRID over-estimation of immunologically active, pre-fusion HA caused by mixed immunoprecipitin rings.
    Wen Y; Palladino G; Xie Y; Ferrari A; Ma X; Han L; Dormitzer PR; Settembre EC
    Vaccine; 2016 Jun; 34(29):3388-95. PubMed ID: 27154389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice.
    Luo M; Tao P; Li J; Zhou S; Guo D; Pan Z
    J Virol Methods; 2008 Dec; 154(1-2):121-7. PubMed ID: 18789973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective immunity afforded by inactivated H5N1 (NIBRG-14) vaccine requires antibodies against both hemagglutinin and neuraminidase in mice.
    Takahashi Y; Hasegawa H; Hara Y; Ato M; Ninomiya A; Takagi H; Odagiri T; Sata T; Tashiro M; Kobayashi K
    J Infect Dis; 2009 Jun; 199(11):1629-37. PubMed ID: 19385735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses.
    Hassantoufighi A; Zhang H; Sandbulte M; Gao J; Manischewitz J; King L; Golding H; Straight TM; Eichelberger MC
    Vaccine; 2010 Jan; 28(3):790-7. PubMed ID: 19887135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
    Hartikka J; Bozoukova V; Yang CK; Ye M; Rusalov D; Shlapobersky M; Vilalta A; Wei Q; Rolland A; Smith LR
    Vaccine; 2009 Oct; 27(46):6399-403. PubMed ID: 19552895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets.
    Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK
    Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice.
    Quintilio W; Kubrusly FS; Iourtov D; Miyaki C; Sakauchi MA; Lúcio F; Dias Sde C; Takata CS; Miyaji EN; Higashi HG; Leite LC; Raw I
    Vaccine; 2009 Jun; 27(31):4219-24. PubMed ID: 19393709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological assessment of plant-derived avian flu H5/HA1 variants.
    Spitsin S; Andrianov V; Pogrebnyak N; Smirnov Y; Borisjuk N; Portocarrero C; Veguilla V; Koprowski H; Golovkin M
    Vaccine; 2009 Feb; 27(9):1289-92. PubMed ID: 19162113
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microcarrier-based MDCK cell culture system for the production of influenza H5N1 vaccines.
    Hu AY; Weng TC; Tseng YF; Chen YS; Wu CH; Hsiao S; Chou AH; Chao HJ; Gu A; Wu SC; Chong P; Lee MS
    Vaccine; 2008 Oct; 26(45):5736-40. PubMed ID: 18761387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying.
    Amorij JP; Meulenaar J; Hinrichs WL; Stegmann T; Huckriede A; Coenen F; Frijlink HW
    Vaccine; 2007 Aug; 25(35):6447-57. PubMed ID: 17673338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the potency, optimal antigen level and lasting immunity of inactivated avian influenza vaccine prepared from H5N1 virus.
    Sasaki T; Isoda N; Soda K; Sakamoto R; Saijo K; Hagiwara J; Kokumai N; Ohgitani T; Imamura T; Sawata A; Lin Z; Sakoda Y; Kida H
    Jpn J Vet Res; 2009 Feb; 56(4):189-98. PubMed ID: 19358446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    J Infect Dis; 2009 Feb; 199(3):405-13. PubMed ID: 19061423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel adjuvant IC31 strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice.
    Riedl K; Riedl R; von Gabain A; Nagy E; Lingnau K
    Vaccine; 2008 Jun; 26(27-28):3461-8. PubMed ID: 18495302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
    Crevar CJ; Ross TM
    Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses.
    Patel A; Tran K; Gray M; Li Y; Ao Z; Yao X; Kobasa D; Kobinger GP
    Vaccine; 2009 May; 27(23):3083-9. PubMed ID: 19428922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.